High Fas expression in gastric carcinoma cells as a factor correlating with the occurrence of metastases to regional lymph nodes

Gryko, Mariusz; Guzińska‐Ustymowicz, Katarzyna; Kiśluk, Joanna; Cepowicz, Dariusz; Kemonä, A; Kędra, Bogusław

doi:10.1016/j.advms.2013.07.005

Cited by 5 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric cancer is another type of tumor that shows a connection between high expression of FAS mRNA and better survival in this study. However, previous studies have reported that the positive expression of FAS protein was correlated with disease progression, such as nodal invasion and advanced stages [28]. Some studies reported that high expression of FAS meant better differentiation of tumor cells [29] and FAS was down-regulated in gastric cancer [30].…”

Section: Discussionmentioning

confidence: 94%

In silico analysis of the prognostic value of FAS mRNA in malignancies

Chen

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: FAS is a classical death receptor involved in the FAS/FAS ligand (FASL) apoptosis pathway and plays a role in anti-tumor activity. Some studies have recently reported that FAS can serve as an oncogene that promotes tumor proliferation and maintains the stemness of tumor cells. Hence, its prognostic value in malignancies remains controversial. Methods: we assessed the prognostic value of FAS mRNA in several types of tumors by online platforms including Kaplan-Meier Plotter and SurvExpress. Results: FAS mRNA was associated with better overall survival (OS) in breast cancer (Hazard ratio (HR): 0.59 [0.47, 0.73]; p=1.5e−06), gastric cancer (HR: 0.65 [0.54, 0.77]; p=8e−07) and non-small-cell lung cancer (NSCLC) (HR: 0.78 [0.69, 0.89]; p=0.00016), especially in lung adenocarcinoma (HR: 0.64 [0.51, 0.81], p=1.7e-04), female lung cancer (HR:0.72 [0.57, 0.9], p=0.0049) and patients who have never smoked (HR: 0.39 [0.21, 0.7], p=0.0012). However, a high level of FAS mRNA expression indicated poorer OS in pancreatic cancer (HR: 1.33 [1.06, 1.66]; p=0.01) and acute myeloid leukemia (AML) (HR: 1.57 [1.02, 2.41], p=0.04). Additionally, FAS showed no prognostic value in renal carcinoma, head and neck carcinoma, hepatic cancer, ovarian cancer, colorectal cancer or glioblastoma. The results from the Cell Miner tool revealed that FAS expression was associated with the sensitivity of tumor cells to cabozantinib and erlotinib. Conclusions: In summary, the dominant function of FAS may vary in different malignancies. FAS mRNA expression was correlated with better OS in breast cancer, gastric cancer and lung cancer, but worse OS in pancreatic cancer and AML. We also suggested that FAS mRNA expression could be a potential biomarker for cabozantinib and erlotinib.

show abstract

Section: Discussionmentioning

confidence: 94%

In silico analysis of the prognostic value of FAS mRNA in malignancies

Chen

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…On the basis of the development of ultrasound, CT, MRI, imaging technology, and computer 3D treatment, interstitial implantation combined with close-distance radiation therapy exhibited better therapeutic value and resulted in better patient vitality. The CT-guided positioning system enables the new type of 125 I radioactive particle to have more extensive application prospects in tumor treatment [19,20]. NSCLC is a common malignant tumor with an increasing incidence and mortality rate year by year.…”

Section: Discussionmentioning

confidence: 99%

The Mechanism of Computed Tomography-Guided 125I Particle in Treating Lung Cancer

Jin

Yang

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundThe incidence of malignant tumor has gradually increased. How to improve the survival and quality of life of patients who lose the opportunity for surgery or who are unwilling to receive surgery remains an obstacle. At present, 125I particle interstitial implant therapy has been applied in a variety of treatments of tumors. However, the mechanism of computed tomography (CT)-guided 125I particle therapy in lung cancer has not been fully elucidated.Material/MethodsA total of 42 patients with advanced non-small cell lung cancer were retrospectively analyzed between January 2013 and December 2013, including 19 patients who received CT-guided 125I particle therapy and 23 patients who received chemotherapy. Curative effect and adverse reactions at 6 months and 12 months were compared and analyzed. A rabbit lung cancer VX2 model was treated by 125I particle implantation therapy under CT guidance. The change in tumor volume was detected. Tumor cell apoptosis was tested by flow cytometry. Bcl-2 and Bax expression were determined by real-time polymerase chain reaction (PCR) and Western blot.Results125I particle therapy obviously reduced tumor volume after 6 months and 12 months. It showed significantly higher efficiency (57.9%, 57.9%) and control (78.9%, 73.7%) than the rates of efficiency and control in the chemotherapy group (P<0.05). 125I particle implantation therapy markedly suppressed rabbit VX2 transplanted tumor cell proliferation, promoted tumor regression, induced tumor cell apoptosis, reduced Bcl-2 expression, and upregulated Bax expression level (P<0.05).ConclusionsCT-guided 125I particle implantation therapy can inhibit tumor proliferation and growth by regulating the expression of apoptosis-related genes and proteins, which is a promising approach in lung cancer treatment.

show abstract

“…If indeed FAS can assume a non-apoptotic role in aggressive cancer, its overexpression in cancer patients may be anticipated. Data relevant to this issue are limited, with only few reports available for ovarian, 57 esophageal, 58 thyroid, 59 gastric, 60 and renal cancers. 61 Using data obtained from the TCGA, we showed that both coding and lncRNA's of FAS were significantly more abundant in seventeen cancer types, including 424 high-grade serous ovarian cancer, compared to normal tissues.…”

Section: Figurementioning

confidence: 99%

Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer

Shinderman-Maman

Weingarten

Moskovich

et al. 2017

Molecular Carcinogenesis

View full text Add to dashboard Cite

The regulation of cancer-relevant genes by the thyroid hormones, 3, 5, 3′-Triiodo-Lthyronine (T3) and L-thyroxine (T4), was recently acknowledged. However, limited data exists on the hormonal effects on gene expression in ovarian cancer, a gynecological malignancy associated with a low cure rate. The expression of fifteen genes involved in DNA repair, cell cycle, apoptosis, and tumor suppression was evaluated in OVCAR-3 and A2780 cell lines, using real-time PCR following short incubation with T3 (1 nM) or T4 (100 nM). The thyroid hormones downregulated the expression of the majority of genes examined. Support for the involvement of the MAPK and PI3K in thyroid hormone-mediated gene expression was shown for a set of genes. FAS expression was inhibited in A2780 cells, while an unexpected induction was demonstrated in OVCAR-3 cells. An analogous effect on the protein levels of FAS receptor and its soluble form was demonstrated by Western blotting. We further established, using primer sets that discriminate between the different RNA isoforms, that the hormones increase the mRNA levels of both coding and non-coding FAS mRNAs. The prevalence of these isoforms, using The Cancer Genome Atlas (TCGA) analysis, was significantly more abundant in 17 cancer types, including ovarian cancer, compared to normal tissues. Our results highlight the role of thyroid hormones in the expression of cancer-relevant-genes in ovarian cancer and provide an important insight into the pathways by which mitogenic and anti-apoptotic effects are exerted. This integrin contains an Arg-Gly-Asp (RGD) recognition site that binds extra cellular matrix (ECM) proteins containing this sequence. At close proximity to the RGD recognition site, a thyroid hormone receptor was described. 1,2 The receptor is complex and includes a site for T3 and a second site for T3 and for L-thyroxine (T4), 3 the principal secretory product of the thyroid gland. Physiological levels of T4 activate the thyroid hormone receptor on αvβ3, whereas supraphysiologic concentrations of T3 are required to achieve stimulation at this Molecular Carcinogenesis. 2018;57:97-105.wileyonlinelibrary.com/journal/mc

show abstract

High Fas expression in gastric carcinoma cells as a factor correlating with the occurrence of metastases to regional lymph nodes

Cited by 5 publications

References 36 publications

In silico analysis of the prognostic value of FAS mRNA in malignancies

In silico analysis of the prognostic value of FAS mRNA in malignancies

The Mechanism of Computed Tomography-Guided 125I Particle in Treating Lung Cancer

Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer

Contact Info

Product

Resources

About